Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients

Critical Care Medicine

Volumn 38, Issue 3, 2010, Pages 826-830

  Cohen, Yves ^a   Karoubi, Philippe ^a   Adrie, Christophe ^b   Gauzit, Rémy ^c   Marsepoil, Thierry ^d   Zarka, Daniel ^e   Clec'H, Christophe ^a  

^a AVICENNE HOSPITAL   (France)

^b DELAFONTAINE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d CENTRE HOSPITALIER DE GONESSE   (France)

^e Centre Hospitalier Robert Ballanger CHRB   (France)

Author keywords

Candida glabrata; Fungemia; Intensive care unit; Prognosis

Indexed keywords

CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; CANDIDA GLABRATA; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FUNGAL COLONIZATION; FUNGEMIA; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; SOLID TUMOR;

EID: 77249091215     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181cc4734     Document Type: Article

References (40)

1. Blumberg HM, Jarvis WR, Soucie JM, et al: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33:177-186
2. Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3:685-702 (Pubitemid 37345347)
3. Vincent JL, Sakr Y, Sprung CL, et al: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34: 344-353
4. Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317
5. Spellberg BJ, Filler SG, Edwards JE Jr: Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-251
6. Banerjee SN, Emori TG, Culver DH, et al: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 86S-89S
7. Jarvis WR, Martone WJ: Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29(Suppl A):19-24
8. Colombo AL, Perfect J, DiNubile M, et al: Global distribution and outcomes for Candida species causing invasive candidiasis: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:470-474
9. Pfaller MA, Diekema DJ, Messer SA, et al: Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilu-tion, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Micro-biol 2003; 41:1440-1446
10. Pappas PG, Kauffman CA, Andes D, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535
11. Olaechea PM, Palomar M, Leon-Gil C, et al: Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23:323-330
12. Krcmery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002; 50:243-260
13. Pappas PG, Rex JH, Sobel JD, et al: Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189
14. Horvath LL, Hospenthal DR, Murray CK, et al: Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J Clin Microbiol 2003; 41:4714-4717
15. Chow JK, Golan Y, Ruthazer R, et al: Factors associated with candidemia caused by non-albicans Candida species versus Candida al-bicans in the intensive care unit. Clin Infect Dis 2008; 46:1206-1213
16. Dimopoulos G, Ntziora F, Rachiotis G, et al: Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: Differences in risk factors and outcome. Anesth Analg 2008; 106:523-529
17. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multi-center study. JAMA 1993; 270:2957-2963
18. McCabe WR, Jackson GG: Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110:847-855
19. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
20. Blot SI, Vandewoude KH, Hoste EA, et al: Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480-485
21. Macphail GL, Taylor GD, Buchanan-Chell M, et al: Epidemiology, treatment and outcome of candidemia: A five-year review at three Canadian hospitals. Mycoses 2002; 45: 141-145
22. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al: Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23:23-30
23. Pappas PG, Rex JH, Lee J, et al: A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-643
24. Panackal AA, Gribskov JL, Staab JF, et al: Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44:1740-1743
25. Abi-Said D, Anaissie E, Uzun O, et al: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-1128 (Pubitemid 127774267)
26. Bross J, Talbot GH, Maislin G, et al: Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am J Med 1989; 87:614-620
27. Karabinis A, Hill C, Leclercq B, et al: Risk factors for candidemia in cancer patients: A case-control study. J Clin Microbiol 1988; 26:429-432
28. Nucci M, Colombo AL: Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002; 21:209-211
29. Wey SB, Mori M, Pfaller MA, et al: Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149:2349-2353
30. Shorr AF, Lazarus DR, Sherner JH, et al: Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007; 35:1077-1083
31. Kunova A, Trupl J, Dluholucky S, et al: Use of fluconazole is not associated with a higher incidence of Candida krusei and other nonalbicans Candida species. Clin Infect Dis 1995; 21:226-227
32. Nguyen MH, Peacock JE Jr, Tanner DC, et al: Therapeutic approaches in patients with can-didemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429-2435
33. Pelz RK, Hendrix CW, Swoboda SM, et al: Double-blind placebo-controlled trial of flu-conazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548
34. Leone M, Albanese J, Antonini F, et al: Long-term epidemiological survey of Candida species: Comparison of isolates found in an intensive care unit and in conventional wards. J Hosp Infect 2003; 55:169-174
35. Almirante B, Rodriguez D, Park BJ, et al: Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43:1829-1835
36. Hajjeh RA, Sofair AN, Harrison LH, et al: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42:1519-1527
37. Sofair AN, Lyon GM, Huie-White S, et al: Epidemiology of community-onset candi-demia in Connecticut and Maryland. Clin Infect Dis 2006; 43:32-39
38. Reller ME, Mallonee AB, Kwiatkowski NP, et al: Use of peptide nucleic acid-fluorescence in situ hybridization for definitive, rapid identification of five common Candida species. J Clin Microbiol 2007; 45:3802-3803
39. Shepard JR, Addison RM, Alexander BD, et al: Multicenter evaluation of the Candida albi-cans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008; 46: 50-55
40. Weinberger M, Leibovici L, Perez S, et al: Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005; 61:146-154